Silexion Therapeutics Corp: Board Resignation; Audit Committee Restored

What Happened

• Silexion Therapeutics Corp filed an 8-K (follow-up to a prior 8-K filed July 31, 2026) reporting that Professor Amnon Peled notified the board of his resignation on July 30, 2026, effective August 1, 2026. His resignation was for personal reasons and not due to any disagreement with the company.
• Immediately upon Professor Peled’s resignation (effective August 1, 2026), the board appointed existing independent director Avner Lushi to the audit committee. Mr. Lushi has been a board member since August 2024 and is Managing Partner & CEO of the Guangzhou Sino-Israel Bio-industry Investment Fund.

Key Details

• Professor Amnon Peled resigned effective August 1, 2026; resignation stated to be for personal reasons, not due to any company disagreement.
• Avner Lushi appointed to the audit committee effective August 1, 2026; board determined he meets Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1) independence requirements.
• Audit committee membership is now three independent directors: Dror J. Abramov (Chair and audit committee financial expert), Ruth Alon, and Avner Lushi.
• The company restored full compliance with Nasdaq audit committee composition rules without relying on the Nasdaq cure-period exception.

Why It Matters

• Restoring a three-member independent audit committee addresses Nasdaq listing requirements and reduces potential governance or listing-risk concerns.
• Having an audit committee financial expert (Dror J. Abramov) and three independent members supports investor confidence in the company’s financial oversight and controls.
• The filing clarifies the change was not due to any disagreement, which may reassure investors about board stability and corporate governance continuity.